Nagata, S. & Tanaka, M. Programmed cell loss of life and the immune system. Nat. Rev. Immunol. 17, 333–340 (2017).
Lu, B. & Finn, O. T-cell loss of life and most cancers immune tolerance. Cell Demise Differ. 15, 70–79 (2008).
Philip, M. & Schietinger, A. CD8+ T cell differentiation and dysfunction in most cancers. Nat. Rev. Immunol. 22, 209–223 (2022).
Morotti, M. et al. Guarantees and challenges of adoptive T-cell therapies for strong tumours. Br. J. Most cancers 124, 1759–1776 (2021).
Flugel, C. L. et al. Overcoming on-target, off-tumour toxicity of CAR T cell remedy for strong tumours. Nat. Rev. Clin. Oncol. 20, 49–62 (2023).
Baker, D. J., Arany, Z., Baur, J. A., Epstein, J. A. & June, C. H. CAR T remedy past most cancers: the evolution of a dwelling drug. Nature 619, 707–715 (2023).
Sterner, R. C. & Sterner, R. M. CAR-T cell remedy: present limitations and potential methods. Blood Most cancers J. 11, 69 (2021).
Rafiq, S., Hackett, C. S. & Brentjens, R. J. Engineering methods to beat the present roadblocks in CAR T cell remedy. Nat. Rev. Clin. Oncol. 17, 147–167 (2020).
Ikeda, H. et al. Immune evasion by way of mitochondrial switch within the tumour microenvironment. Nature 638, 225–236 (2025).
Saha, T. et al. Intercellular nanotubes mediate mitochondrial trafficking between most cancers and immune cells. Nat. Nanotechnol. 17, 98–106 (2022).
Elia, I. et al. Tumor cells dictate anti-tumor immune responses by altering pyruvate utilization and succinate signaling in CD8+ T cells. Cell Metab. 34, 1137–1150. e1136 (2022).
Kovács, S. A., Fekete, J. T. & Győrffy, B. Predictive biomarkers of immunotherapy response with pharmacological functions in strong tumors. Acta Pharmacol. Sin. 44, 1879–1889 (2023).
Goode, A. et al. Faulty recognition of LC3B by mutant SQSTM1/p62 implicates impairment of autophagy as a pathogenic mechanism in ALS-FTLD. Autophagy 12, 1094–1104 (2016).
Johansen, T. & Lamark, T. Selective autophagy mediated by autophagic adapter proteins. Autophagy 7, 279–296 (2011).
Guo, X. et al. Mito-bomb: concentrating on mitochondria for most cancers remedy. Adv. Mater. 33, e2007778 (2021).
Kumar, P., Nagarajan, A. & Uchil, P. D. Evaluation of cell viability by the lactate dehydrogenase assay. Chilly Spring Harb. Protoc. 2018, 465–468 (2018).
Jia, F. et al. Stabilizing RNA nanovaccines with transformable hyaluronan dynamic hydrogel for sturdy most cancers immunotherapy. Adv. Funct. Mater. 33, 2204636 (2023).
Yamashita, A. et al. The actions and metabolism of lysophosphatidylinositol, an endogenous agonist for GPR55. Prostaglandins Different Lipid Mediat. 107, 103–116 (2013).
Zhou, X.-L., Guo, X., Track, Y.-P., Zhu, C.-Y. & Zou, W. The LPI/GPR55 axis enhances human breast most cancers cell migration through HBXIP and p-MLC signaling. Acta Pharmacol. Sin. 39, 459–471 (2018).
Raskov, H., Orhan, A., Christensen, J. P. & Gögenur, I. Cytotoxic CD8+ T cells in most cancers and most cancers immunotherapy. Br. J. Most cancers 124, 359–367 (2021).
Hegde, P. S. & Chen, D. S. Prime 10 challenges in most cancers immunotherapy. Immunity 52, 17–35 (2020).
Leone, P. et al. MHC class I antigen processing and presenting equipment: group, operate, and defects in tumor cells. JNCI: J. Natl Most cancers Inst. 105, 1172–1187 (2013).
